Laminar Pharma, Inc.
Laminar Pharma is a Spanish biotech company founded in 2006 as a spin-off of the University of the Balearic Islands. It specializes in designing and developing drugs based on a novel therapeutic approach called melitherapy, targeting membrane lipids to treat various diseases, including cancer and neurological disorders. The company is committed to translational research, innovation, and addressing unmet medical needs, with a focus on oncology, rare diseases, and pediatric patients. Laminar Pharma has received multiple awards, grants, and recognitions for its scientific and business achievements, and is actively involved in clinical trials, collaborations, and funding rounds to advance its therapies.
Industries
Nr. of Employees
small (1-50)
Laminar Pharma, Inc.
Edificio Naorte, Bloque A, 1ª planta. Puerta 3, 07121 Palma de Mallorca, Baleares (Spain)
Products
Clinical-stage investigational membrane-lipid regulator for oncology (hydroxylated fatty acid)
An investigational hydroxylated fatty-acid class therapeutic that modulates membrane lipid composition; evaluated in multiple clinical studies including early-phase safety/PK/PD studies and a Phase IIb/III glioblastoma trial with combination radiochemotherapy.
Preclinical therapeutic candidates targeting neurodegeneration and inflammation
Preclinical molecules derived from a membrane-lipid therapy platform under investigation for neurological and inflammatory indications.
Clinical-stage investigational membrane-lipid regulator for oncology (hydroxylated fatty acid)
An investigational hydroxylated fatty-acid class therapeutic that modulates membrane lipid composition; evaluated in multiple clinical studies including early-phase safety/PK/PD studies and a Phase IIb/III glioblastoma trial with combination radiochemotherapy.
Preclinical therapeutic candidates targeting neurodegeneration and inflammation
Preclinical molecules derived from a membrane-lipid therapy platform under investigation for neurological and inflammatory indications.
Services
Design and operational management of multicentre clinical trials including site coordination, safety monitoring, PK/PD assessments and study readouts.
Discovery and preclinical development services focused on molecules that modulate membrane lipid composition and domain organization to alter cellular signalling.
Recombinant overexpression and purification of membrane-associated and other proteins to support structural, biochemical and inhibitor-development workflows.
Preparation and management of regulatory filings, agency interactions and designation applications to support clinical development and trial initiation.
Patent filing and portfolio management for therapeutic candidates, and negotiation/execution of licensing agreements.
Design and operational management of multicentre clinical trials including site coordination, safety monitoring, PK/PD assessments and study readouts.
Discovery and preclinical development services focused on molecules that modulate membrane lipid composition and domain organization to alter cellular signalling.
Recombinant overexpression and purification of membrane-associated and other proteins to support structural, biochemical and inhibitor-development workflows.
Preparation and management of regulatory filings, agency interactions and designation applications to support clinical development and trial initiation.
Patent filing and portfolio management for therapeutic candidates, and negotiation/execution of licensing agreements.
Expertise Areas
- Clinical trial management (Phase I–III, including paediatric studies)
- Oncology drug development (glioblastoma and other solid tumours)
- Membrane lipid-targeted therapeutic discovery
- Biomarker discovery and translational research
Key Technologies
- Membrane lipid modulation therapeutics
- Hydroxylated fatty acid small-molecule chemistry
- Recombinant protein expression and purification
- Cell-based functional assays
News & Updates
Results from a clinical trial showing promising data for LAM561 in combination therapy for glioblastoma.
The company has finished recruiting patients for its phase 2b/3 clinical trial of LAM561 in glioblastoma.
The independent data monitoring committee recommended advancing the CLINGLIO trial to the next stage.
Initial results from clinical trials showing the potential of LAM561 in treating glioma.
Scientific publications and reviews on the role of lipids in cancer and other diseases.
Award recognizing scientific advances in the biomedical field.
Results from a clinical trial showing promising data for LAM561 in combination therapy for glioblastoma.
The company has finished recruiting patients for its phase 2b/3 clinical trial of LAM561 in glioblastoma.
The independent data monitoring committee recommended advancing the CLINGLIO trial to the next stage.
Initial results from clinical trials showing the potential of LAM561 in treating glioma.
Scientific publications and reviews on the role of lipids in cancer and other diseases.
Award recognizing scientific advances in the biomedical field.